Stuart A McDougall1, Matthew D Heath2, Matthias F Kramer3, Murray A Skinner2. 1. ARCINOVA, Willowburn Avenue, Alnwick, Northumberland, NE66 2JH, UK. 2. Allergy Therapeutics plc, Dominion Way, Worthing, BN14 8SA, UK. 3. Bencard Allergie GmbH, Messerschmittstr. 4, 80992 München, Germany.
Abstract
BACKGROUND: Investigation into the absorption, distribution and elimination of aluminium in rat after subcutaneous aluminium adjuvant formulation administration using ICP-MS is described. METHOD & RESULTS: Assays were verified under the principles of a tiered approach. There was no evidence of systemic exposure of aluminium, in brain or in kidney. Extensive and persistent retention of aluminium at the dose site was observed for at least 180 days after administration. CONCLUSION: This is the first published work that has quantified aluminium adjuvant retention based on the quantity of aluminium delivered in a typical allergy immunotherapy course. The results indicate that the repeated administration of aluminium-containing adjuvants will likely contribute directly and significantly to an individual's body burden of aluminium.
BACKGROUND: Investigation into the absorption, distribution and elimination of aluminium in rat after subcutaneous aluminium adjuvant formulation administration using ICP-MS is described. METHOD & RESULTS: Assays were verified under the principles of a tiered approach. There was no evidence of systemic exposure of aluminium, in brain or in kidney. Extensive and persistent retention of aluminium at the dose site was observed for at least 180 days after administration. CONCLUSION: This is the first published work that has quantified aluminium adjuvant retention based on the quantity of aluminium delivered in a typical allergy immunotherapy course. The results indicate that the repeated administration of aluminium-containing adjuvants will likely contribute directly and significantly to an individual's body burden of aluminium.
Entities:
Keywords:
ADME; ICP-MS; ICP-MS sample digestion; SCIT; adjuvant; body burden; subcutaneous; tiered approach; tissue distribution
Authors: Gustavo Cabral-Miranda; Matthew D Heath; Ariane C Gomes; Mona O Mohsen; Eduardo Montoya-Diaz; Ahmed M Salman; Erwan Atcheson; Murray A Skinner; Matthias F Kramer; Arturo Reyes-Sandoval; Martin F Bachmann Journal: Vaccines (Basel) Date: 2017-09-27
Authors: Gustavo Cabral-Miranda; Matthew D Heath; Mona O Mohsen; Ariane C Gomes; Paul Engeroff; Amy Flaxman; Fabiana M S Leoratti; Aadil El-Turabi; Arturo Reyes-Sandoval; Murray A Skinner; Matthias F Kramer; Martin F Bachmann Journal: Vaccines (Basel) Date: 2017-05-02
Authors: Deborah S Leuthard; Agathe Duda; Sandra N Freiberger; Sina Weiss; Isabella Dommann; Gabriele Fenini; Emmanuel Contassot; Matthias F Kramer; Murray A Skinner; Thomas M Kündig; Matthew D Heath; Pål Johansen Journal: J Immunol Date: 2018-03-28 Impact factor: 5.422
Authors: Matthew D Heath; Mona O Mohsen; Pieter-Jan de Kam; Thalia L Carreno Velazquez; Simon J Hewings; Matthias F Kramer; Thomas M Kündig; Martin F Bachmann; Murray A Skinner Journal: Front Immunol Date: 2020-11-24 Impact factor: 7.561
Authors: Gandhi F Pavón-Romero; Maria Itzel Parra-Vargas; Fernando Ramírez-Jiménez; Esmeralda Melgoza-Ruiz; Nancy H Serrano-Pérez; Luis M Teran Journal: Cells Date: 2022-01-08 Impact factor: 6.600
Authors: Martin Feindor; Matthew D Heath; Simon J Hewings; Thalia L Carreno Velazquez; Simon Blank; Johannes Grosch; Thilo Jakob; Peter Schmid-Grendelmeier; Ludger Klimek; David B K Golden; Murray A Skinner; Matthias F Kramer Journal: Toxins (Basel) Date: 2021-09-01 Impact factor: 4.546